the drug (such as SLE), we conditionally recommend against treating with prophylactic HCQ. As with any unproven treatment, this therapy may be considered in specific circumstances, depending on a patient's values and preferences and after a discussion about risks and benefits. Anti-Ro/SSA and/or anti-La/SSB antibodies in pregnancy. Neonatal lupus erythematosus (NLE) describes several fetal and infant manifestations caused by or associated with maternal anti-Ro/SSA (commonly) and anti-La/SSB